BioCryst’s (BCRX) Peramivir - A Lifesaver

Ed Liston
Follow this user

Posted on 11/06/09 at 8:04am by Ed Liston

Biocryst Pharmaceuticals’ (NASDAQ: BCRX) new drug, Peramivir has proved to be a life-saver against the dreaded H1N1 virus, according to a story reported from a hospital in Seattle.

Peramivir is still an intravenous, experimental drug, is still under clinical trials and is not yet approved by the FDA. But on October 23rd, the FDA had granted permission to use it on patients in case of emergency.

The question for both the pharma firm and investors is about how much of the drug it can really sell. Biocryst estimates a total of 120, 000 cases by the end of this year, and also large demand from outside the US.

Bookmark/Search this post with:
  • Twitter
  • Facebook
  • Buzz Up!
  • StumbleUpon
  • Digg
  • Reddit
  • MySpace
  • LinkedIn
  • del.icio.us
You are not watching this post, click to start watching

Posted in
There are 1 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.

Biocryst can make immediate

by Anonymous on 11/06/09 11:01am

Biocryst can make immediate delivery of 130,000 courses of Peramivir based upon 5 days treatment/course. However, many patients are being kept on Peramivir for 10 days reducing the number of patients that can be treated to 65,000. Based upon a 10 day treatment, the Center for Disease Control (CDC) has ordered 5000 courses which probably won't last long. The remaining courses are available on a first come first served basis. It would be a shame if product produced here int he US that could save Amercian lives wound up being delivered to another country because of a failure of our government to stockpile enough Peramivir. What is this administration thinking???

Post new comment

The content of this field is kept private and will not be shown publicly.